NCL urges FDA and consumers to take action as GLP-1 shortage ends, but infodemic continues Media Contact: Lisa McDonald, Vice President of Communications, (202)-207-2829 May 22 Conclusion of Mass Compounded GLP-1s Should Bring Clarity but Confusion Reigns Washington, DC Despite the end of the GLP-1 shortage and May 22 FDA-issued deadline for companies to stop mass compounding of the products, the National Consumers League (NCL) is concerned that the epidemic of GLP-1 misinformation will continue to confuse consumers with fake products that can put their health at risk
Adults: Take one to two capsules twice daily
Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE, Zimring JC, Hansen KC, Hod EA, Spitalnik SL, DAlessandro A (2020) COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status
The full search string was: (GLP-1 receptor agonist OR glucagon-like peptide-1 receptor agonist OR semaglutide OR liraglutide OR tirzepatide) AND (pregnancy OR preconception OR fertility OR reproductive health) AND (safety OR exposure OR discontinuation OR outcomes)
Mild edema or water retention: Occasional, dose-related